Jupiter Neurosciences (JUNS) Income from Continuing Operations (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Income from Continuing Operations of 2871248.0 for Q4 2025, down 105.51% year-over-year from 52077806.68 in Q4 2024, and up 73.47% quarter-over-quarter from 10820742.0 in Q3 2025.
Jupiter Neurosciences (JUNS) Income from Continuing Operations (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Income from Continuing Operations for 3 consecutive years, with 2871248.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 105.51% year-over-year to 2871248.0; the TTM figure through Dec 2025 stood at 19649375.0 (down 204.34% YoY), while the FY2025 annual figure was 10680888.0, up 89.92% from the prior year.
- Income from Continuing Operations advanced to 2871248.0 in Q4 2025 per JUNS's latest filing, from 10820742.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 613314.0 in Q2 2024 and bottomed at 10820742.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 2824494.7 across 3 years, with a median of 1727982.0 in 2023.
- On a YoY basis, Income from Continuing Operations climbed as much as 105.51% in 2025 and fell as far as 556.11% in 2025.
- Jupiter Neurosciences' Income from Continuing Operations stood at 616518.0 in 2023, then slumped by 126.61% to 1397110.0 in 2024, then tumbled by 105.51% to 2871248.0 in 2025.
- Business Quant data shows JUNS's Income from Continuing Operations at 2871248.0 in Q4 2025, 10820742.0 in Q3 2025, and 4023997.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | -2.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.87 Mn |
| Sep 30, 2025 | -10.82 Mn |
| Jun 30, 2025 | -4.02 Mn |
| Mar 31, 2025 | -1.93 Mn |
| Dec 31, 2024 | -1.40 Mn |
| Sep 30, 2024 | -3.81 Mn |
| Jun 30, 2024 | -613,314.00 |
| Mar 31, 2024 | -636,389.00 |
| Dec 31, 2023 | -616,518.00 |
| Sep 30, 2023 | -1.52 Mn |